This is the quote the excites me, as it suggests technology will be extended out to other tumour types, beyond pancreatic....
“Designation of the OncoSil device as a breakthrough device is a validation of our platform technology which can be used to treat multiple solid tumour types such as liver, biliary duct and of course pancreatic cancer,”
Ann: Oncosil breakthrough device receives CE Marking approval, page-62
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.5¢ | $11.53K | 2.265M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5730762 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 18790968 | 25 |
View Market Depth
| Last trade - 12.48pm 17/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |
